Home » Drug Information » FDA Approved Drugs » 1996
Medical Areas: Endocrinology | Oncology
View By:YearCompanyConditionsTherapeutic AreasDrug Names
Elliotts B Solution (buffered intrathecal electrolyte/dextrose injection)
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: Orphan Medical
Approval Status: Approved October 1996
Treatment Area: meningeal leukemia or lymphocytic lymphoma
Elliotts B Solution has been approved as a treatment for
meningeal leukemia or lymphocytic lymphoma. Leukemia and lymphomas
are two of the main types of childhood cancers.
Adverse reactions may occur with any given intrathecal injection
due to the chemotherapy or the technique of intrathecal
Mechanism of Action
Elliotts B Solution is comparable to cerebrospinal fluid in pH,
electrolyte composition, glucose content, and osmolarity. Elliotts
B Solution maintains the pH of methotrexate sodium and cytarabine
closer to physiologic pH and provides a buffer capacity not found
in other diluents, such as preservative-free saline.
Cradock, J.C., et al. "Evaluation of some pharmaceutical
aspects of intrathecal methotrexate sodium, cytarabine, and
hydrocortisone sodium succinate." American Journal of Hospital
Pharmacy (1978); 35:402.
Acute lymphocytic leukemia (ALL) is primarily a childhood
leukemia, which accounts for approximately 57% of childhood
leukemias. There are approximately 6,000 cases of ALL in the United